NoGeneST™ Anti-SMN2 Aptamer, aSMN2 aptamer

Name: NoGeneST™ Anti-SMN2 Aptamer, aSMN2 aptamer
SKU: NRYF-0625-HZ105
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ105]

Aptamer designed to specifically recognize Survival Motor Neuron 2 protein, the key therapeutic target for Spinal Muscular Atrophy (SMA).

Target:: SMN2

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Relevant Diseases

Spinal Muscular Atrophy

Properties

Size

5 nmol. 10 nmol. 50 nmol

Soluble In

PBS; buffer system with Serum; other

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

SMN2

Full Name

Survival Motor Neuron Protein

Alternative Names

SMNC

Gene ID

6607

Uniprot ID

Q16637

Target Overview

SMN2 is a gene that is nearly identical to SMN1. However, a critical single nucleotide difference causes most of the mRNA transcribed from the SMN2 gene to be improperly spliced, resulting in the exclusion of a key section (exon 7). This leads to the production of a truncated and unstable protein that is largely non-functional. In patients with Spinal Muscular Atrophy (SMA) who lack a functional SMN1 gene, the SMN2 gene is their only source of SMN protein. The severity of the disease often correlates with the number of SMN2 gene copies a person has. This makes SMN2 the primary therapeutic target for SMA, with major treatment strategies focused on modulating its splicing to increase the production of full-length, functional protein.

Publications